Distribution of vasoactive intestinal polypeptide (VIP) binding in circular muscle and characterization of VIP binding in canine small intestinal mucosa.

Mao YK, Barnett W, Coy DH, Tougas G, Daniel EE

The Journal of pharmacology and experimental therapeutics1 Sept 1991Cited by 12 (Europe PMC)

PMID1653848DOI10.1016/s0022-3565(25)20310-xPepBankPUB-01653848

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueActivity measurement
In canine intestinal mucosa preparations, the highest [125I]VIP binding was in the P2 fraction, matching the locations of [3H]saxitoxin binding and VIP-immunoreactive content.
In plain wordsIn lab tests on dog intestine tissue, VIP bound most in the same fraction that held nerve-ending markers.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableLocalization of [125I]VIP binding
Study
dogn: not reported in source
Canine small intestinal mucosa preparations
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
The highest [125I]VIP binding was located in the P2 fraction and was correlated with the locations of maximal [3H]saxitoxin binding and VIP-immunoreactive content.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study examined the localization and characterization of [125I]vasoactive intestinal polypeptide (VIP) binding to synaptosomes and enterocyte membranes using preparations made from homogenized canine intestinal mucosa and compared it to [3H]saxitoxin binding and VIP-immunoreactive content…
Report a problemFND-0165384801
02LabEx vivo tissueActivity measurement
A synaptosome-enriched fraction of canine intestinal mucosa had a high density of saturable VIP receptors (352 +/- 26.40 fmol/mg) with high affinity (Kd 0.23 nM) for [125I]VIP.
In plain wordsIn lab tests on dog intestine tissue, nerve-ending fractions held many VIP receptors that bound VIP tightly.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP receptor density and affinity in synaptosome-enriched fraction
Study
dogn: not reported in source
Canine small intestinal mucosa preparations
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Measurements
receptor density
352 fmol/mg
synaptosome-enriched fraction
Kd
0.23 nM
synaptosome-enriched fraction
Source sentences
Summary
A fraction enriched in synaptosomes contained a high density of saturable VIP receptors (352 +/- 26.40 fmol/mg) having high affinity (Kd, 0.23 nM) for [125I]VIP.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study examined the localization and characterization of [125I]vasoactive intestinal polypeptide (VIP) binding to synaptosomes and enterocyte membranes using preparations made from homogenized canine intestinal mucosa and compared it to [3H]saxitoxin binding and VIP-immunoreactive content…
Report a problemFND-0165384802
03LabEx vivo tissueActivity measurement
Competition binding experiments suggested a high and a low affinity VIP binding site in canine intestinal mucosa.
In plain wordsIn lab tests on dog intestine tissue, VIP appeared to bind to two kinds of sites, one strong and one weak.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableNumber of VIP binding sites in competition experiments
Study
dogn: not reported in source
Canine small intestinal mucosa preparations
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Competition binding experiments suggested the presence of two binding sites, a high and a low affinity binding site.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study examined the localization and characterization of [125I]vasoactive intestinal polypeptide (VIP) binding to synaptosomes and enterocyte membranes using preparations made from homogenized canine intestinal mucosa and compared it to [3H]saxitoxin binding and VIP-immunoreactive content…
Report a problemFND-0165384803
04LabEx vivo tissueActivity measurement
In competition for [125I]VIP binding, VIP was the most potent competitor, ahead of peptide histidine isoleucine, secretin and the other VIP analogues tested.
In plain wordsIn lab tests on dog intestine tissue, VIP competed for its binding sites better than related peptides and VIP analogues.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableCompetition potency of VIP and related peptides
Study
dogn: not reported in source
Canine small intestinal mucosa preparations
Comparator
Peptide histidine isoleucine, secretin and VIP analogues
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
The order of competition potency was VIP greater than peptide histidine isoleucine greater than secretin greater than peptide histidine methionine greater than or equal to [D-Ala4]VIP greater than or equal to [Phe1]VIP greater than VIP10-28 greater than [4-Cl-D-Phe6-Leu17]VIP.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study examined the localization and characterization of [125I]vasoactive intestinal polypeptide (VIP) binding to synaptosomes and enterocyte membranes using preparations made from homogenized canine intestinal mucosa and compared it to [3H]saxitoxin binding and VIP-immunoreactive content…
Report a problemFND-0165384804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.